FDA Grants Traditional Approval for Selpercatinib for Medullary Thyroid Cancer with a RET Mutation By Ogkologos - November 6, 2024 795 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LIBRETTO-531 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR How to Plan a ‘Safecation’ August 17, 2020 Study Probes Awareness of Alcohol’s Link to Cancer January 18, 2023 New Imaging Tool Could Predict Whether Hormone Therapy Will Work in... February 4, 2021 Sotorasib Shows Promising Activity and Acceptable Safety in Patients with Previously... January 10, 2023 Load more HOT NEWS How to Spend Time with Friends and Family Now that COVID... Could A Diabetes Diagnosis Help Detect Pancreatic Cancer Early? Changes to chromosomes impact how children’s brain tumours respond to treatment France Bans all Textured and Polyurethane Breast Implants Amid BIA-ALCL Cancer...
